查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1825656

2025年遊離DNA（cfDNA）檢測全球市場報告

Cell Free DNA (cfDNA) Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年，遊離DNA (cfDNA) 檢測市場將呈指數級成長，到2029年將達到243.4億美元，複合年成長率為22.4%。預測期間的成長可歸因於以下因素：個人化醫療的轉變、醫療基礎設施的加強、人口老化和癌症發生率的上升、精準醫療的普及、液態切片技術的認知度和接受度的提高，以及對cfDNA研究的投資和資金籌措的增加。預測期內的主要趨勢包括液態切片技術的普及、新一代定序 (NGS) 技術的進步、人工智慧和機器學習在cfDNA檢測中的整合、照護現場cfDNA檢測的發展，以及雲端基礎資料儲存和分析平台的普及。

未來五年22.4%的預測成長率，較我們先前對該市場的預測略有下降0.5%。這一下降主要源自於美國與其他國家之間關稅的影響。徵收關稅可能會增加從韓國和瑞典進口的基於次世代定序(NGS) 的遊離cfDNA套件和數位聚合酵素鏈鎖反應(PCR) 系統的成本，從而擾亂美國液態切片的普及。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，其影響也將更加廣泛。

癌症發生率的上升預計將推動未來遊離DNA (cfDNA) 檢測市場的成長。癌症是一組複雜的疾病，其特徵是體內細胞異常生長和擴散。這些細胞會侵入並損害正常組織，如果不及時治療，將帶來巨大的風險。癌症發生率的上升是由於人口老化、生活方式的改變、環境影響以及檢測和診斷方法的進步等因素造成的。 cfDNA 檢測可以在早期（通常在症狀出現之前）檢測出癌症相關的基因突變。這種早期檢測有助於及時干預，並且在早期發現癌症可以改善患者的預後和存活率。例如，世界衛生組織 (WHO) 在 2024 年 2 月預測，到 2050 年，新增癌症病例數將超過 3,500 萬，比 2022 年估計的 2,000 萬例增加 77%。因此，癌症發生率的上升正在推動遊離DNA (cfDNA) 檢測市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球遊離DNA（cfDNA）檢測：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球遊離DNA（cfDNA）檢測市場：成長率分析
  • 全球遊離DNA（cfDNA）檢測市場表現：規模與成長，2019-2024年
  • 全球遊離DNA（cfDNA）檢測市場預測：2024-2029年及2034年規模及成長
  • 全球遊離DNA（cfDNA）檢測：總潛在市場（TAM）

第6章 市場細分

  • 全球遊離DNA（cfDNA）檢測市場：依產品、績效及預測，2019-2024年、2024-2029年、2034年
  • 供體來源的遊離DNA
  • 循環遊離細胞腫瘤DNA
  • 遊離胎兒DNA
  • 全球遊離DNA（cfDNA）檢測市場（依平台、績效及預測），2019-2024年，2024-2029年，2034年
  • 次世代定序（NGS）
  • rPCR和多重PCR
  • qPCR和dPCR
  • 其他平台
  • 全球遊離DNA（cfDNA）檢測市場：應用、績效及預測（2019-2024年、2024-2029年、2034年）
  • 腫瘤學
  • 非侵入性產前檢測（NIPT）
  • 婦科
  • 移植
  • 其他用途
  • 全球遊離 DNA (cfDNA) 檢測市場：依供體來源遊離 DNA 細分（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 器官移植監測
  • 檢測移植物排斥反應
  • 全球遊離DNA（cfDNA）檢測市場：依循環遊離腫瘤DNA細分（按類型）、實際及預測，2019-2024年、2024-2029年、2034年
  • 癌症檢測
  • 微量殘存疾病監測
  • 液態生物檢體
  • 全球遊離DNA（cfDNA）檢測市場：按遊離胎兒DNA（類型）細分，實際及預測，2019-2024年，2024-2029年，2034年
  • 非侵入性產前檢測（NIPT）
  • 胎兒遺傳疾病篩檢

第7章 區域和國家分析

  • 全球遊離DNA（cfDNA）檢測市場：區域分析、預測與成長，2019-2024年、2024-2029年、2034年
  • 全球遊離DNA（cfDNA）檢測市場：依國家/地區、績效及預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 無細胞DNA（cfDNA）檢測市場：競爭格局
  • 無細胞DNA（cfDNA）檢測市場：公司簡介
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
    • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Illumina Inc.
  • Qiagen NV
  • Exact Sciences Corporation
  • Bio-Techne Corporation
  • Natera Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories Inc.
  • Invitae Corporation
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Integrated DNA Technologies Inc.
  • Caris Life Sciences Inc.
  • Twist Bioscience Corporation
  • Adaptive Biotechnologies Corporation
  • Biodesix Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年遊離DNA（cfDNA）檢測市場：哪些國家將提供新機會
  • 2029年遊離DNA（cfDNA）檢測市場：細分領域帶來新機會
  • 2029年遊離DNA（cfDNA）檢測市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r29752u

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic technique that examines DNA fragments freely circulating in the bloodstream. This testing method is integral to liquid biopsy procedures, enabling the detection and analysis of genetic mutations and alterations without resorting to traditional tissue biopsies.

The primary products within the cell-free DNA (cfDNA) testing market include donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA originates from transplanted donor organs or tissues and can be found in the recipient's bloodstream. Various platforms are utilized for cfDNA testing, such as next-generation sequencing (NGS), real-time PCR (rPCR) and multiplex PCR, quantitative PCR (qPCR) and digital PCR (dPCR), among others. These platforms are applied across various domains including oncology, non-invasive prenatal testing (NIPT), gynecology, transplantation, and other medical conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell-free DNA (cfDNA) testing market research report is one of a series of new reports from The Business Research Company that provides cell-free DNA (cfDNA) testing market statistics, including cell-free DNA (cfDNA) testing industry global market size, regional shares, competitors with a cell-free DNA (cfDNA) testing market share, detailed cell-free DNA (cfDNA) testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-free DNA (cfDNA) testing industry. This cell-free DNA (cfDNA) testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell free dna (cfdna) testing market size has grown exponentially in recent years. It will grow from $8.74 billion in 2024 to $10.84 billion in 2025 at a compound annual growth rate (CAGR) of 24.0%. The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.

The cell free dna (cfdna) testing market size is expected to see exponential growth in the next few years. It will grow to $24.34 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.

The forecast of 22.4% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. liquid biopsy adoption by increasing costs for Next-Generation Sequencing(NGS)-based cell-free cfDNA kits and digital Polymerase Chain Reaction(PCR) systems imported from South Korea and Sweden, potentially delaying cancer detection and raising diagnostic costs by $200-500 per test. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer is expected to drive the growth of the cell-free DNA (cfDNA) testing market in the future. Cancer encompasses a complex group of diseases characterized by abnormal cell growth and spread in the body. These cells can invade and damage normal tissue, posing significant risks if left unchecked. The rise in cancer prevalence is attributed to factors such as aging populations, lifestyle changes, environmental influences, and advancements in detection and diagnostic methods. cfDNA testing detects genetic mutations linked to cancer at early stages, often before symptoms manifest. This early detection enables timely interventions, enhancing patient outcomes and survival rates by identifying cancer in its initial phases. For example, in February 2024, the World Health Organization (WHO) projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Hence, the increasing prevalence of cancer is fueling the growth of the cell-free DNA (cfDNA) testing market.

Key players in the cell-free DNA (cfDNA) testing market prioritize the development of innovative technologies, such as liquid biopsy tests that offer heightened sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic changes. Liquid biopsy tests involve diagnostic procedures enabling oncologists to assess circulating cell-free DNA released by tumor cells, facilitating personalized and targeted therapy strategies. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a new liquid biopsy test tailored for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) from tumor cells through a standard blood draw, ensuring minimal invasiveness and rapid results. It enhances access to precision oncology by identifying clinically actionable biomarkers across various common cancers such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

In February 2022, Laboratory Corporation of America Holdings (LabCorp), a US-based clinical healthcare company, acquired Personal Genome Diagnostics Inc. for an undisclosed sum. This acquisition positions LabCorp to advance its existing liquid biopsy capabilities and broaden its array of state-of-the-art next-generation sequencing (NGS)-based genomic profiling tools for cancer, positioning it at the forefront of improving patient outcomes. Personal Genome Diagnostics Inc. specializes in precision oncology diagnostics, including cell-free DNA testing technology.

Major companies operating in the cell free DNA (CFDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

North America was the largest region in the cell-free DNA (CFDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (CFDNA)) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell free DNA (CFDNA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Free DNA (cfDNA) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell free dna (cfdna) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell free dna (cfdna) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell free dna (cfdna) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA
  • 2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms
  • 3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications
  • Subsegments:
  • 1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection
  • 2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy
  • 3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT); Fetal Genetic Disorder Screening
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Illumina Inc.; Qiagen N.V.; Exact Sciences Corporation; Bio-Techne Corporation; Natera Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; Invitae Corporation; Foundation Medicine Inc.; Guardant Health Inc.; Integrated DNA Technologies Inc.; Caris Life Sciences Inc.; Twist Bioscience Corporation; Adaptive Biotechnologies Corporation; Biodesix Inc.; Biocept Inc.; Personal Genome Diagnostics Inc.; Agena Bioscience Inc.; Menarini Silicon Biosystems Inc.; Circulogene Theranostics LLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cell Free DNA (cfDNA) Testing Market Characteristics

3. Cell Free DNA (cfDNA) Testing Market Trends And Strategies

4. Cell Free DNA (cfDNA) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cell Free DNA (cfDNA) Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cell Free DNA (cfDNA) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cell Free DNA (cfDNA) Testing Market Growth Rate Analysis
  • 5.4. Global Cell Free DNA (cfDNA) Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cell Free DNA (cfDNA) Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cell Free DNA (cfDNA) Testing Total Addressable Market (TAM)

6. Cell Free DNA (cfDNA) Testing Market Segmentation

  • 6.1. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Donor-Derived Cell-Free DNA
  • Circulating Cell-Free Tumor DNA
  • Cell-Free Fetal DNA
  • 6.2. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next Generation Sequencing (NGS)
  • rPCR and Multiplexed PCR
  • qPCR and dPCR
  • Other Platforms
  • 6.3. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Non-Invasive Prenatal Test (NIPT)
  • Gynecology
  • Transplantation
  • Other Applications
  • 6.4. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Donor-Derived Cell-Free DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Organ Transplant Monitoring
  • Graft Rejection Detection
  • 6.5. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Circulating Cell-Free Tumor DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Detection
  • Minimal Residual Disease Monitoring
  • Liquid Biopsy
  • 6.6. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Cell-Free Fetal DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Invasive Prenatal Testing (NIPT)
  • Fetal Genetic Disorder Screening

7. Cell Free DNA (cfDNA) Testing Market Regional And Country Analysis

  • 7.1. Global Cell Free DNA (cfDNA) Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cell Free DNA (cfDNA) Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cell Free DNA (cfDNA) Testing Market

  • 8.1. Asia-Pacific Cell Free DNA (cfDNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cell Free DNA (cfDNA) Testing Market

  • 9.1. China Cell Free DNA (cfDNA) Testing Market Overview
  • 9.2. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cell Free DNA (cfDNA) Testing Market

  • 10.1. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cell Free DNA (cfDNA) Testing Market

  • 11.1. Japan Cell Free DNA (cfDNA) Testing Market Overview
  • 11.2. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cell Free DNA (cfDNA) Testing Market

  • 12.1. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cell Free DNA (cfDNA) Testing Market

  • 13.1. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cell Free DNA (cfDNA) Testing Market

  • 14.1. South Korea Cell Free DNA (cfDNA) Testing Market Overview
  • 14.2. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cell Free DNA (cfDNA) Testing Market

  • 15.1. Western Europe Cell Free DNA (cfDNA) Testing Market Overview
  • 15.2. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cell Free DNA (cfDNA) Testing Market

  • 16.1. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cell Free DNA (cfDNA) Testing Market

  • 17.1. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cell Free DNA (cfDNA) Testing Market

  • 18.1. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cell Free DNA (cfDNA) Testing Market

  • 19.1. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cell Free DNA (cfDNA) Testing Market

  • 20.1. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cell Free DNA (cfDNA) Testing Market

  • 21.1. Eastern Europe Cell Free DNA (cfDNA) Testing Market Overview
  • 21.2. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cell Free DNA (cfDNA) Testing Market

  • 22.1. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cell Free DNA (cfDNA) Testing Market

  • 23.1. North America Cell Free DNA (cfDNA) Testing Market Overview
  • 23.2. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cell Free DNA (cfDNA) Testing Market

  • 24.1. USA Cell Free DNA (cfDNA) Testing Market Overview
  • 24.2. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cell Free DNA (cfDNA) Testing Market

  • 25.1. Canada Cell Free DNA (cfDNA) Testing Market Overview
  • 25.2. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cell Free DNA (cfDNA) Testing Market

  • 26.1. South America Cell Free DNA (cfDNA) Testing Market Overview
  • 26.2. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cell Free DNA (cfDNA) Testing Market

  • 27.1. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cell Free DNA (cfDNA) Testing Market

  • 28.1. Middle East Cell Free DNA (cfDNA) Testing Market Overview
  • 28.2. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cell Free DNA (cfDNA) Testing Market

  • 29.1. Africa Cell Free DNA (cfDNA) Testing Market Overview
  • 29.2. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cell Free DNA (cfDNA) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Cell Free DNA (cfDNA) Testing Market Competitive Landscape
  • 30.2. Cell Free DNA (cfDNA) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cell Free DNA (cfDNA) Testing Market Other Major And Innovative Companies

  • 31.1. Illumina Inc.
  • 31.2. Qiagen N.V.
  • 31.3. Exact Sciences Corporation
  • 31.4. Bio-Techne Corporation
  • 31.5. Natera Inc.
  • 31.6. Myriad Genetics Inc.
  • 31.7. NeoGenomics Laboratories Inc.
  • 31.8. Invitae Corporation
  • 31.9. Foundation Medicine Inc.
  • 31.10. Guardant Health Inc.
  • 31.11. Integrated DNA Technologies Inc.
  • 31.12. Caris Life Sciences Inc.
  • 31.13. Twist Bioscience Corporation
  • 31.14. Adaptive Biotechnologies Corporation
  • 31.15. Biodesix Inc.

32. Global Cell Free DNA (cfDNA) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Free DNA (cfDNA) Testing Market

34. Recent Developments In The Cell Free DNA (cfDNA) Testing Market

35. Cell Free DNA (cfDNA) Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Cell Free DNA (cfDNA) Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cell Free DNA (cfDNA) Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cell Free DNA (cfDNA) Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer